U-NEURON Chairman Dr. Frank Chien Projects Turnaround to Profitability Next Year
U-NEURON is targeting the multi-billion-dollar blue ocean market for male erectile dysfunction (ED) while simultaneously activating its dual engines in healthcare and medical aesthetics. Chairman Dr. Frank Chien expects company losses to decrease this year, with a projected turnaround to profitability next year.
U-NEURON Chairman Dr. Frank Chien Projects Turnaround to Profitability Next Year U-NEURON is targeting the multi-billion-dollar blue ocean market for male erectile dysfunction (ED) while simultaneously activating its dual engines in healthcare and medical aesthetics. Chairman Dr. Frank Chien expects company losses to decrease this year, with a projected turnaround to profitability next year.

 

By leveraging its proprietary R&D technologies into high-end medical aesthetics, skincare, and nutraceutical applications, U-NEURON’s dual-engine business model breaks through the traditional bottleneck of prolonged R&D cycles faced by conventional drug developers. As stem cell and exosome technologies are integrated into commercial applications and expanded through brand partnerships, Chairman Dr. Frank Chien projects the company will achieve profitability next year.

Dr. Chien stated that U-NEURON is the world’s first company to secure U.S. patents for isolation and culture technologies of amniotic fluid stem cells, as well as the only biotech firm in Asia focusing on amniotic fluid stem cells for novel drug R&D. Deeply rooted in regenerative medicine, U-NEURON has built a comprehensive patent portfolio in amniotic fluid stem cells and exosomes. Using this foundation, the company has established an R&D platform supporting a diversified product pipeline spanning novel therapeutics, cosmeceuticals, and functional health foods.

U-NEURON noted that while the current market for male erectile dysfunction is vast, existing therapies (such as oral PDE5 inhibitors like Viagra) offer only short-term symptom relief via vasodilation. These options come with potential cardiovascular risks and side effects, and fail to reverse underlying vascular and neural damage. Consequently, a massive unmet medical need remains for moderate-to-severe ED patients, including those with complex neurovascular injuries caused by diabetes, post-radical prostatectomy nerve damage, or non-responsiveness to traditional oral medications.

In response, U-NEURON introduced its amniotic fluid stem cell candidate, which aims to achieve fundamental tissue and neural repair via a single intracavernosal injection, offering potential curative efficacy and superior safety profiles. According to international market research, the global ED therapeutics market is projected to expand at a compound annual growth rate (CAGR) of 8.69% from 2025 to 2034, reaching $6.74 billion by 2034. U-NEURON highlighted that its novel drug specifically targets the high-value segment comprising over 20% of ED patients suffering from diabetes or post-prostatectomy nerve damage, representing immense market potential.

In response, U-NEURON introduced its amniotic fluid stem cell candidate, which aims to achieve fundamental tissue and neural repair via a single intracavernosal injection, offering potential curative efficacy and superior safety profiles. According to international market research, the global ED therapeutics market is projected to expand at a compound annual growth rate (CAGR) of 8.69% from 2025 to 2034, reaching $6.74 billion by 2034. U-NEURON highlighted that its novel drug specifically targets the high-value segment comprising over 20% of ED patients suffering from diabetes or post-prostatectomy nerve damage, representing immense market potential.

https://www.mirrormedia.mg/story/20260325fin004